Innate and adaptive immune pathways in nasal mucosa

The innate and adaptive immune pathways in the nasal mucosa represent a complex integrated system rather than a single molecular target. The innate component provides the first line of defense through physical barriers, antimicrobial peptides, and pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) found on epithelial cells and innate lymphoid cells (ILCs) (PubMed, PMID: 31622570). The adaptive component involves the organized lymphoid tissue of the nose (NALT), where antigen-presenting cells activate T and B lymphocytes, leading to the production of secretory IgA and the orchestration of specialized effector responses, such as the Th2-driven inflammation characteristic of allergic rhinitis (NIH, StatPearls). Dysregulation of these pathways is a primary driver of chronic inflammatory diseases of the upper airway, including nasal polyposis and chronic rhinosinusitis. Pharmacological intervention usually targets specific nodes within these pathways, such as the IL-4/IL-13 signaling axis or IgE-mediated mast cell degranulation, to restore mucosal homeostasis. Because this entry describes a broad biological system and anatomical location rather than a specific protein or receptor, it is classified as an incorrect target designation for structured drug-target profiling.

Other names

Nasal mucosal immunityUpper airway immune responseNasal-associated lymphoid tissue (NALT) pathwaysMucosal immune system of the nose

Drugs interacting with these pathways typically function by inhibiting specific inflammatory cytokines (e.g., IL-4, IL-5, IL-13), neutralizing immunoglobulin E (IgE), or activating glucocorticoid receptors to suppress broad transcriptional programs of inflammation (StatPearls, 2023). Biologics specifically block receptors or ligands within the adaptive arm to prevent Th2-mediated eosinophilic recruitment (JACI, 2020).